Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
CMSC 2026|
ATMRD 2026|
AAIC 2026|
Parkinsonism Practical Guide
Advertisement

Sneha Mantri, MD, MS

Advertisement

Articles by Sneha Mantri, MD, MS

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease

ByMarco Meglio,Sneha Mantri, MD, MS
December 12th 2025

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

    1

    FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment

    2

    Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

    3

    Mitophagy Activator Urolithin A Enters Phase 2 Alzheimer Trial of APOE4 Carriers

    4

    Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease

    5

    Inside the World's First Neural Stem Cell Trial for Huntington Disease

    • About Us
    • Advisory Board
    • Editorial
    • Contact Us
    • Advertise
    • Contact MJH LS
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    • Contagion Live
    • CGT Live
    • Neurology Live
    • HCP Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    • Patient Care Online
    HCP Live Network
    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us